Abiopharma

🔍 MacLellan Robert F. (Executive)

Company: PRICE T ROWE GROUP INC (TROW)

Report Date: 2026-03-30

Detailed Transactions and Holdings:

• Acquired 206 shares of Common Stock at $89.03 per share (Direct)
  Date: 2026-03-30 | Code: A | equity_swap_involved: false | shares_owned_after: 52,965.83 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: This is pursuant to the T. Rowe Price Group, Inc. 2017 Non-Employee Director Equity Plan with respect to dividends declared by the issuer on it's Common Stock. These shares were credited as fully-vested dividend reinvestment shares.